Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature

Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature

Abstract Background Autoimmune polyendocrine syndrome type II (APS-2) is a rare constellation of autoimmune hypoadrenalism, thyroid dysfunction and/or type 1 diabetes (T1DM), usually occurring in the 3rd or 4th decades and associated with a human leukocyte antigen (HLA) DR3 or DR4 serotype. We detai...

Full description

Bibliographic Details
Main Authors: Ashray Gunjur, Oliver Klein, Damien Kee, Jonathan Cebon
Format: Article
Language:English
Published: BMJ Publishing Group 2019-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune checkpoint inhibitor
PD1 inhibitor
Pembrolizumab
Poly-endocrinopathy
Diabetes mellitus
Hypoadrenalism
Online Access:http://link.springer.com/article/10.1186/s40425-019-0713-y

Internet

http://link.springer.com/article/10.1186/s40425-019-0713-y

Similar Items